Literature DB >> 18219042

Benign prostatic hyperplasia. Part 2--management.

Timothy J Wilt1, James N'Dow.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18219042      PMCID： PMC2213816          DOI： 10.1136/bmj.39433.670718.AD

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  19 in total

1.  Guideline for the primary care management of male lower urinary tract symptoms.

Authors:  M J Speakman; R S Kirby; A Joyce; P Abrams; R Pocock
Journal:  BJU Int       Date:  2004-05       Impact factor: 5.588

Review 2.  Laser prostatectomy for benign prostatic obstruction.

Authors:  R M Hoffman; R MacDonald; T J Wilt
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 3.  The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis.

Authors:  Christopher Chapple; Vik Khullar; Zahava Gabriel; Julie Ann Dooley
Journal:  Eur Urol       Date:  2005-03-22       Impact factor: 20.096

Review 4.  Pygeum africanum for benign prostatic hyperplasia.

Authors:  T Wilt; A Ishani; R Mac Donald; I Rutks; G Stark
Journal:  Cochrane Database Syst Rev       Date:  2002

5.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

Authors:  John D McConnell; Claus G Roehrborn; Oliver M Bautista; Gerald L Andriole; Christopher M Dixon; John W Kusek; Herbert Lepor; Kevin T McVary; Leroy M Nyberg; Harry S Clarke; E David Crawford; Ananias Diokno; John P Foley; Harris E Foster; Stephen C Jacobs; Steven A Kaplan; Karl J Kreder; Michael M Lieber; M Scott Lucia; Gary J Miller; Mani Menon; Douglas F Milam; Joe W Ramsdell; Noah S Schenkman; Kevin M Slawin; Joseph A Smith
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

Review 6.  Serenoa repens for benign prostatic hyperplasia.

Authors:  T Wilt; A Ishani; R Mac Donald
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 7.  Terazosin for benign prostatic hyperplasia.

Authors:  T J Wilt; R W Howe; I R Rutks; R MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2002

8.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

9.  The National Prostatectomy Audit: the clinical management of patients during hospital admission.

Authors:  M Emberton; D E Neal; N Black; M Harrison; M Fordham; M P McBrien; R E Williams; K McPherson; H B Devlin
Journal:  Br J Urol       Date:  1995-03

10.  Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?

Authors:  M J Barry; W O Williford; Y Chang; M Machi; K M Jones; E Walker-Corkery; H Lepor
Journal:  J Urol       Date:  1995-11       Impact factor: 7.450
View more
  2 in total

1.  Benign prostatic hyperplasia: alpha1 adrenoreceptor antagonists and cataract surgery.

Authors:  Nathaniel E Knox Cartwright
Journal:  BMJ       Date:  2008-02-09

2.  Disease identification based on ambulatory drugs dispensation and in-hospital ICD-10 diagnoses: a comparison.

Authors:  Patricia Halfon; Yves Eggli; Anne Decollogny; Erol Seker
Journal:  BMC Health Serv Res       Date:  2013-10-31       Impact factor: 2.655
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.